Studies have indicated that humans evolved on a diet of PUFA with an \( n-6:n-3 \) ratio of approximately 1:1, while current estimates of the typical North American diet are 15:1 (reviewed in Simopoulos[1]). The change in ratios is considered to be attributed to an increased intake of foods containing \( n-6 \) fatty acids such as vegetable oils, namely maize and soyabean, with a reduced intake of long-chain \( n-3 \) PUFA from foods such as fresh oily fish, namely salmon and mackerel (reviewed in Black & Sharpe[2]). This high \( n-6:n-3 \) ratio in the diet has been suggested to play a role in the pathogenesis of a number of chronic inflammatory diseases including CVD, diabetes, Crohn’s disease as well as allergy[3–10]. Indeed, an association between higher \( n-6 \) fatty acids in maternal serum and the appearance of allergic disease in their children during the first 6 years of life[9].

These associations may be due, at least partially, to the fact that \( n-6 \) fatty acids give rise to PGD\(_2\), a major mediator of allergic inflammation produced by mast cells following activation[11,12]. Both PGD\(_2\) receptors, D prostanoid receptor 1 (DP1) and DP2, influence inflammatory cell chemotaxis (T helper type 2 (Th2) cells, eosinophils and basophils), with DP1 inhibiting and DP2 mediating this effect[13–16]. DP2 is also called CRTh2 (chemoattractant receptor-homologous molecule expressed on T helper type 2 cells) and is considered a marker of Th2 cells in humans[17]. PGD\(_{2}\)–CRTh2 signalling mediates the expression of the Th2 cytokines IL-4, IL-5 and IL-13[12,14], and therefore this pathway may influence allergic sensitisation, since both IL-4 and IL-13 instruct B cells to isotype switch to IgE[18,19].
There are a number of studies investigating whether re-balancing the n-6:n-3 ratio would prove beneficial and/or protective to the development of allergy. In mouse models of dietary supplementation with α-linolenic acid, significantly lower IgE antibody response against ovalbumin (ova), mortality from anaphylactic shock (20), reduced proliferation of CD4⁺ splenic T cells and increased expression of the inhibitor molecule cytotoxic T-lymphocyte antigen 4 (CTLA-4) have been observed. In one study, it has been shown that administration of aerosolised DHA reduced airway hyper-responsiveness in a mouse model of asthma (22).

Evidence for the potential efficacy of n-3 fatty acid administration in human subjects also exists. A case–control study of Japanese children showed that 10 months of EPA/DHA supplementation significantly improved asthma symptoms (23), while a large cross-sectional study found an inverse association between fish intake and the prevalence of asthma and allergic rhinitis (24,25). Recently, n-3 administration has been shown to reduce inflammation in response to low-dose allergen challenge in human subjects (26). There are a number of studies investigating the effects of in utero exposure to maternal fish oil supplementation during pregnancy. This approach has been shown to result in inverse correlations between the level of DHA and both IL-4 and IL-13 (27,28) as well as fewer children who developed allergic sensitisation (29,30). However, the mechanism(s) for these effects have not yet been described.

Here we report that isolated splenocytes from ova-sensitised mice receiving an n-3 fatty acid-enriched diet during early life exhibit lower IL-4 and IL-13 expression. DHA also attenuated IL-13 expression from human Th2 cells, through the inhibition of promoter activation and transcription factor binding. These data indicate the potential of n-3 fatty acids to attenuate IL-13 expression, which suggests that they may subsequently reduce allergic sensitisation and the development of allergic disease.

Materials and methods

Dietary exposure of mice to a DHA-enriched diet

Experiments were performed according to the protocols approved by the Animal Ethics Board of the University of Alberta. Pregnant BALB/c mice timed to give birth on the same day were obtained from the Health Sciences Laboratory Animal Services breeding facility at the University of Alberta on day 14 of gestation. They were fed nutritionally adequate semi-purified high-fat (15 %, w/w of diet) diets being a DHA-enriched (1 %, w/w of diet, using Marinol®; Lipid Nutrition) or control diet (0 % DHA) starting at the time of delivery (Table 1). The macronutrient (including fat content) and micronutrient content of the diet is as reported previously (31) except for the fat composition provided in Table 1. Both diets provided similar polysaturated:saturated fat ratios (0.5) but differed in the ratio of n-6:n-3, due to the replacement of the n-6 fatty acid linoleic acid by DHA. The control diet had an n-6:n-3 fatty acid ratio of 13:2, while the n-6:n-3 fatty acid ratio for the DHA-enriched diet was 2:1. The complete fatty acid composition of the two diets, analysed by GLC, is provided in Table 1. Pups were then weaned to the maternal diet at 3 weeks, and this was continued until the end of the experiment. At 8 and 9 weeks of age, mice were sensitised with ova by an intraperitoneal injection of 0.9% sterile saline (0.5 ml) containing 10 μg ova (Sigma) and 2 mg Al(OH)3 (MP Biomedicals), as we recently demonstrated that it is sufficient for allergic sensitisation (32). After 14 d (week 10), single cell suspensions (1.25 × 10⁷/ml) were prepared from the spleen as described previously (33).

<table>
<thead>
<tr>
<th>Fatty acids</th>
<th>DHA</th>
<th>Control</th>
</tr>
</thead>
<tbody>
<tr>
<td>∑SFA</td>
<td>60</td>
<td>59</td>
</tr>
<tr>
<td>∑MUFA</td>
<td>10</td>
<td>10</td>
</tr>
<tr>
<td>∑PUFA</td>
<td>30</td>
<td>30</td>
</tr>
<tr>
<td>∑n-6 fatty acids</td>
<td>20:7</td>
<td>27:7</td>
</tr>
<tr>
<td>∑n-3 fatty acids</td>
<td>8:6</td>
<td>2:1</td>
</tr>
<tr>
<td>Linoleic acid (18:2n-6)</td>
<td>2:0</td>
<td>2:1</td>
</tr>
<tr>
<td>EPA (20:5n-3)</td>
<td>1:0</td>
<td>0:0</td>
</tr>
<tr>
<td>DHA (22:6n-3)</td>
<td>5:7</td>
<td>0:0</td>
</tr>
</tbody>
</table>

Cells were stimulated (48 h) with ova (100 μg/ml) or concavalin A (Con A, 2.5 μg/ml; MP Biomedicals). This concentration was based on pilot studies from our laboratory with rodent cells (from animals fed the high-fat control diet) stimulated for 48 h with a low (2.5 μg/ml, n 6) or high (5 μg/ml, n 8) concentration of Con A. We calculated a stimulation index (rate of [%]H]thymidine uptake by stimulated cells [%]H]thymidine uptake by unstimulated cells) of 6.2 (SE 4.0) v. 10.7 (SE 4.0) and the amount of IL-2 in the media to be 900 (SE 200) pg/ml v. 5000 (SE 450) pg/ml for the low v. high concentration of Con A. The experiments were performed with 2.5 μg/ml, a concentration considered to represent an early response to stimulation. Levels of IL-13, IL-4, IL-10 and interferon-γ (IFN-γ) were detected by ELISA according to the manufacturer’s instructions (eBioscience). The detectable range was 4–500 pg/ml and averages of duplicates were used for statistical analysis.

Characterisation of mouse splenocytes

Flow cytometry was used to determine cell phenotypes in the isolated spleen cells as described previously (34). All supplies were purchased from ThermoFisher Scientific with the exception of the antibodies. Monoclonal fluorescent antibodies against mouse CD3-PE, CD4-PE, CD8-PE, CD25-APC, CD19-FTC, MHCIIE-PE, CD86-PE cy.5, CD11c-APC, CD11b-FTC and the corresponding isotype controls were purchased from eBioscience. Briefly, cells were washed twice with 4% fetal calf serum (FCS) in PBS (4 g/l) and incubated (30 min) with the antibodies in combination. The cells were then washed again two times with buffer and fixed with a 1% (w/v) paraformaldehyde PBS solution. The proportion of positive cells for each marker was determined by flow cytometry (FACSCalibur) and analysed using CellQuest software (Becton Dickinson). Unstained cells and isotype controls were used to adjust the gate on the splenocyte population and to determine background and colour compensation.
Primary human T helper type 2 cells

The present study was conducted according to the guidelines laid down in the Declaration of Helsinki and all procedures involving human subjects/patients were approved by the University of Alberta Human Ethics Board. Written informed consent was obtained from all subjects. Th2 cells were generated by isolating CD4⁺ T cells from peripheral blood mononuclear cells by negative selection using the CD4⁺ Isolation Kit II (Miltenyi Biotech). Purity was greater than 96% as assessed by flow cytometry. Cytokines and antibodies were from eBiosciences, Inc. CD4⁺ T cells (2 × 10⁶ cells/ml) were cultured in X-VIVO-15 medium (Lonza) supplemented with 10% fetal bovine serum (HyClone; Fisher Scientific) and 1% penicillin, streptomycin and glutamine (Gibco; Life Technologies). Cells were primed for 3 d (2 × 10⁶ cells/ml) with antibodies against CD3 and CD28 (plate bound, 1 μg/ml) under Th2-polarising conditions (recombinant human (rh) IL-2, 5 ng/ml; rhIL-4, 10 ng/ml; neutralising antibodies against IFN-γ, 1 μg/ml; IL-12, 1 μg/ml; eBiosciences). Cells were rested for 4 d in rhIL-2 (5 ng/ml), IL-4 (10 ng/ml), anti-IFN-γ and anti-IL-12 (1 μg/ml). On day 7, CRTh2⁺ cells were similarly maintained on weekly cycles of 3 d priming (anti-CD3, anti-CD28 and rhIL-2) followed by a 4 d rest (rhIL-2, 5 ng/ml). The experiments were performed with five independently differentiated lines ranging from day 10 to day 66 of culture with Hyclone fetal bovine serum (10%), which contained DHA (0–79 μg/ml), EPA (0–27 μg/ml) and arachidonic acid (AA, 1–62 μg/ml) as determined by GLC.

Chemoattractant receptor-homologous molecule expressed on T helper type 2 cells and T helper type 2 cytokine staining

Surface staining of CRTh2 was performed at 4°C by first blocking (30 min) with normal rat IgG (Invitrogen; Life Technologies), then addition (30 min) of anti-CRTh2 primary antibody (CRTh2-biotin; Miltenyi Biotech) or isotype (rat IgG2a; ABD Serotech) followed by addition (30 min) of Streptavidin-APC (eBiosciences). To assess the influence of DHA on the Th2 cell phenotype, DHA (10 μM; Cayman Chemical) was added to the CRTh2⁺ cells during the resting phase, the time point of optimal CRTh2 expression (L. Cameron, unpublished results).

For intracellular cytokine staining, Th2 cells were stimulated (1–3 × 10⁶ cells/ml) for 4 h with phorbol myristate acetate (PMA) (20 ng/ml), ionomycin (1 μM) and brefeldin A (10 μg/ml) (Sigma Aldrich) in the presence or absence of DHA, AA or oleic acid (OA; 10 μM). Cells were fixed with paraformaldehyde (4%; Sigma Aldrich) and permeabilised with saponin (0.4%; Sigma Aldrich). IL-13-PE and IL-4-Alexa 488 antibodies (JES10-5A2 and 8D4-8, respectively; BD Pharmingen) and isotypes (rat IgG1k-PE and mouse IgG1k-Alexa 488) were incubated on ice (30 min), washed and fluorescence read immediately by flow cytometry (FACS Calibur; Becton Dickson).

Transient transfections

Jurkat T cells (clone E6-1; American Type Culture Collection) were transiently transfected (5 × 10⁶) with a firefly luciferase reporter construct containing 369 bp of the IL-13 promotor located immediately upstream of exon 1 (IL-13-369pro/Luc; 10 μg) and a constitutive reporter containing Renilla luciferase (pRL-TK; 10 ng; Promega) to control for transfection efficiency. Cells were electroporated with a square wave using one pulse of 50 ms (240 V, BTX, ECM 830; Harvard Apparatus, Inc.). These conditions resulted in transfection efficiency >30%.

In all experiments, cells were stimulated with PMA (20 ng/ml) and ionomycin (1 μM) and stimulated with or without DHA, AA or OA (4 μM) immediately following transfection. Luciferase activity was assessed after 16–18 h incubation with the Dual Luciferase Assay (Promega) according to the manufacturer’s instructions. Protein concentration was determined using the bicinchoninic acid protein acid kit (Pierce; Fisher Scientific). Firefly luciferase results were normalised for transfection efficiency (as determined by Renilla luciferase activity) and protein concentrations, and expressed as relative luciferase activity (luciferase counts/μg protein). All data are represented as fold induction by PMA/ionomycin (stimulated/unstimulated). For each experiment, the relative luciferase activity of a control sample without any fatty acid addition was set at 1 and the DHA, AA and OA samples were compared with this reference sample.

Nuclear extracts

Jurkat and Th2 cells (12 × 10⁶) were stimulated with PMA (20 ng/ml) and ionomycin (1 μM) in the presence or absence of DHA (10 μM, 3 h). Cells were harvested, pelleted, washed in cold 1× PBS and resuspended in ice-cold buffer A (10 mM-HEPES, 30 mM-MgCl₂, 40 mM-KCl, 10 mM-dithiothreitol (DTT), 5% glycerol, 0.20% NP-40 (nonyl phenoxypolyethoxylethanol), 1 mM-phenylmethylsulfonyl fluoride (PMSF), 5 mM-β-glycerophosphate, 1 mM-benzamidine, 1 mM-orthosodium vanadate, 1 mM-sodium fluoride, 10 μg antipain/ml, 10 μg aprotinin/ml, 10 μg leupeptin/ml, 10 μg pepstatin/ml: Sigma Aldrich). PMSF and DTT were added to buffer A immediately before use. Cell lysis was monitored by trypan blue, and once swollen, cells were centrifuged at 13,200 rpm for 2 min at 4°C. Nuclear pellets were resuspended in an appropriate volume of ice-cold buffer C (420 mM-NaCl, 10 mM-HEPES, 25% glycerol, 1.5 mM-MgCl₂, 0.2 mM-EDTA, 1 mM-DTT, 1 mM-PMSF, 5 mM-β-glycerophosphate, 1 mM-benzamidine, 1 mM-orthosodium vanadate, 1 mM-sodium fluoride, 10 μg antipain/ml, 10 μg aprotinin/ml, 10 μg leupeptin/ml, 10 μg pepstatin/ml), incubated on ice (20 min) and centrifuged at 13,200 rpm for 2 min at 4°C. PMSF and DTT were added to buffer C immediately before use. Supernatants containing nuclear proteins were recovered and aliquots frozen immediately in liquid N₂ and stored at −80°C.

Electromobility shift assay

Gel shift assays were performed using an oligonucleotide probe (PR) spanning -112/-87 (5’cggcattgatgaggaattggata-tttgaa) of the IL-13 5’-flanking region. Double-stranded
DHA inhibits IL-13 transcription

Statistical analysis

Data are represented as means with their standard errors of the mean. Statistical analysis was performed using Sigma-Plot software (version 11; Systat Software Inc.). Statistical differences in IL-13 and IL-4 expression from unstimulated compared with ova-stimulated splenocytes from animals fed the two diets were determined using the two-sample Student’s t test; IL-10 and IFN-γ using the Mann–Whitney U test. Con A stimulations were examined for significant increases using the Mann–Whitney U test. Differences in the percentages of IL-13- and IL-4-expressing human Th2 cells and IL-13 promoter activity with or without DHA were determined using the paired Student’s t test; experiments including lipid controls were determined with one-way ANOVA (repeated measures). \( P < 0.05 \) was considered as significant.

Results

Influence of a DHA-enriched diet on the relative abundance of spleen cell types

To characterise the effect of a DHA-enriched diet on the different cell populations within the spleen, flow cytometry was performed with antibodies for phenotypic markers. This analysis revealed no significant differences in the proportion of T cells, B cells, dendritic cells or macrophages, although there were trends for a reduction in the percentage of activated T cells and macrophages (Table 2).

A DHA-enriched diet reduces antigen-specific production of T helper type 2 cytokines

Supplementation of pregnant dams with fish oil, a source of long-chain n-3 PUFAs including EPA and DHA, has been associated with reduced levels of IL-13 in the cord blood \(^{27} \). To follow up on these observations, we developed a mouse model to investigate whether dietary intake of DHA during early life could similarly modulate the immune system. To gain a broad understanding of the response, we examined Th2 and
of Th2 cells, we assessed the expression of CRTh2, as a marker of human Th2 cells\(^{(17,35)}\). Fig. 2(a) shows representative flow cytometry staining for CRTh2 on human Th2 cells after a 4 d rest with IL-2 (5 ng/ml), the time point of maximal CRTh2 expression, in the presence or absence of DHA (10 \(\mu M\)). This concentration is within or below the range used by numerous other \textit{in vitro} studies investigating the influence of DHA on immune function\(^{(36–38)}\). Fig. 2(b) shows that 50·1 (SE 10·2) % of cells were expressing CRTh2 in resting conditions and 54·1 (SE 8·6) % when DHA was added. These findings suggest that DHA does not affect the maintenance of the Th2 phenotype.

DHA inhibits the expression of IL-13 protein

Since there was no influence on the percentage of Th2 cells, we next assessed whether DHA could directly inhibit Th2 cytokine expression. The percentage of IL-13 expressing human Th2 cells stimulated (4 h) with PMA (20 ng/ml) and ionomycin (1 \(\mu M\)) in the presence or absence of DHA (10 \(\mu M\)) was assessed. Fig. 3(a) shows that this stimulation resulted in 41·4 (SE 6·0) % of cells expressing IL-13, which was reduced in each experiment by DHA on average by 32% (\(n = 12\), \(P<0.01\)). Interestingly, the inhibitory effect was more potent (40%) when the Th2 population was moderately IL-13 positive (<50%) compared with highly IL-13 positive (>50%, 9·5%), although reductions were significant in both populations (\(P<0.05\)). This response was DHA-specific since control experiments performed with diluent (ethanol), AA or OA (10 \(\mu M\)) showed no change (Fig. 3(b)). However, significant reductions in the percentage of cells expressing IL-4 when stimulated in the presence of DHA (\(n = 9\)), AA or OA were not observed, although there was a trend (\(n = 4\), Fig. 3(c) and (d)). DHA treatment also did not affect total cell numbers (data not shown). These results show that DHA inhibits the expression of IL-13 in differentiated Th2 cells.

DHA abrogates transcriptional activation of the human IL-13 promoter

Since we demonstrated that DHA could inhibit the protein expression of IL-13, we next asked whether this inhibition was due to direct interference with IL-13 promoter activation. We transiently transfected Jurkat T cells, a line commonly used for studying transcriptional regulation of T-cell genes\(^{(39)}\), with a luciferase reporter construct containing a fragment of the human IL-13 promoter (IL-13-369pro/Luc). Fig. 4(a) shows a 25-fold induction of IL-13 promoter activity in response to the stimulation of PMA (20 ng/ml) and ionomycin (1 \(\mu M\)); this induction was lower with cells stimulated in the presence of DHA (16-fold, \(P<0.01\)). The effect of DHA was specific, since control lipids (AA and OA) did not reduce IL-13 promoter activity (10 \(\mu M\); Fig. 4(b)). These data indicate that the \(n\)-3 fatty acid metabolite DHA can inhibit IL-13 promoter activation.

DHA abrogates transcription factor binding to the human IL-13 promoter

Since DHA reduced IL-13 promoter activity, we hypothesised that it also affects transcription factor binding. Electromobility

| Table 3. Cytokine levels from splenocytes (Mean values with their standard errors) |
|--------------------|-------|-------|-------|-------|
|                    | US    | Con A |
| **In vivo diet**   | Mean  | SE    | Mean  | SE    |
| IL-13              |       |       |       |       |
| DHA                | 5·7   | 12·2  | 1211·0* | 265·9 |
| Control            | 9·3   | 1·9   | 1190·7* | 227·7 |
| IL-4               |       |       |       |       |
| DHA                | 0·6   | 5·0   | 90·7*  | 19·4  |
| Control            | 9·7   | 2·2   | 68·7*  | 11·9  |
| IL-10              |       |       |       |       |
| DHA                | 3·0   | 5·8   | 565·7* | 107·3 |
| Control            | 14·9  | 7·1   | 459·0* | 51·8  |
| IFN-\(\gamma\)     |       |       |       |       |
| DHA                | 10·9  | 12·8  | 955·2* | 80·9  |
| Control            | 129·8 | 52·8  | 930·8* | 111·8 |

US, unstimulated; Con A, concavalin A; IFN-\(\gamma\), interferon-\(\gamma\). * Mean value was significantly different from that of US splenocytes (\(P<0.01\); Mann–Whitney U test).
shift assays (EMSA) with nuclear extracts from PMA (20 ng/ml)- and ionomycin (1 μM)-stimulated Jurkat cells (Fig. 5(a)) and human Th2 cells (Fig. 5(b)) were performed. *In silico* analysis identified putative transcription factor sites and antibodies were used to confirm the binding. Fig. 5(a) and (b) shows a number of bands (lanes 2 and 8), compared with free probe (containing no extract; lanes 1 and 7). Specific binding was confirmed by competition with 100-fold molar excess of unlabelled oligonucleotide (lanes 3 and 9). A polyclonal anti-CREB antibody recognising a number of CREB family members revealed that three of the bands were CREB proteins, since they were supershifted (lanes 4 and 10). The fourth was the CREB family member ATF-2, since the band was lost with anti-ATF2 antibody (lanes 5 and 11). No alteration in these bands was observed with control antibody (IgG; lanes 6 and 12).

Fig. 5(c) is an EMSA with nuclear extracts from Th2 cells stimulated with PMA/ionomycin in the presence or absence of DHA (10 μM). As shown in Fig. 5(b), ATF2 and CREB were identified by antibody supershift (lanes 3 and 4, respectively). The binding intensity of both these proteins was reduced with extracts from cells stimulated in the presence of DHA (lane 2) compared with stimulation alone (lane 1). The data are representative of four independent experiments using extracts generated from three different human Th2 lines. These findings indicate that the DHA effect on IL-13 transcription is mediated, at least in part, by the inhibition of CREB/ATF-2 binding to the IL-13 promoter both in Jurkat and Th2 cells.

**Discussion**

While there has been some controversy, various studies have indicated that *n*-3 fatty acid supplementation holds promise for treating and/or preventing allergic disease. An inverse association between fish intake and the prevalence of asthma has been reported, and *n*-3 fatty acid administration to children with asthma resulted in reduced symptoms. More recently, investigators have focused on determining whether targeting sensitisation may be more effective than established disease. Indeed, *n*-3 supplementation during pregnancy was associated with lower levels of cord blood IL-13 and allergic symptoms in children. Inverse correlations between fish intake and sensitisation have also been reported, and early introduction of fresh oily fish into children’s diet was associated with protection from eczema at 2 years of age. The present results using a DHA-enriched diet are consistent with these findings (that used a mixture of EPA + DHA) and indicate that the effect may involve the inhibition of IL-13 and IL-4. Since these cytokines are essential for isotype switching to IgE, the results suggest that DHA may reduce allergic sensitisation. However, further studies such as determining the presence of specific IgE, the effect on IgE-mediated mast cell activation and animal models of allergen challenge are needed to confirm whether the DHA-mediated reduction in Th2 cytokine production influences allergic sensitisation.

We selected a level of 1 % (w/w) DHA because our previous work using a rodent model demonstrated its influence on...
T-cell responses and altered the composition of DHA in the dam's milk (43). In the present study, the animals were exposed to elevated levels of DHA from birth until maturity (10 weeks) through the dam's milk and then due to being weaned onto the diet. Therefore, while this regimen is associated with lower IL-13 and IL-4 expression, we are not able to determine the relative importance of the early chronic/prolonged feeding on allergic sensitisation. This is an interesting distinction that should be made in future studies, particularly in light of the data reported by Oien et al. (41) indicating that early introduction of fish to children's diet was highly protective against eczema.

We examined cytokine expression to determine the influence on Th2 immunity, and the present data clearly show that splenocytes from DHA-fed mice exhibited lower antigen-specific IL-13 and IL-4 expression, unlike activation with Con A. Although we used a time point and concentration of Con A that were previously determined to be optimal for splenocyte proliferation and IL-2 production, lower Th2 cytokine expression from cells of DHA-fed mice may have been observed with lower Con A concentration and/or time points. Alternatively, Con A and CD3 have recently been shown to use different pathways and kinetics for Ca influx and the recruitment of Ca-permeable non-selective cation channels (44). Therefore, the complex regulation of Ca may play a role in the inability of DHA to inhibit Th2 cytokine expression in response to this concentration of Con A. There were no significant effects of the diet on the relative percentage or concentration of splenic T cells (CD4⁺ or CD8⁺), B cells or dendritic cells, or their expression of CD25, major histocompatibility complex II (MHC II) or CD86.

In vitro experiments with human Th2 cells treated with DHA demonstrated an inhibitory effect on the percentage of IL-13-expressing but not IL-4-expressing cells. IL-4 is the crucial cytokine for Th2 differentiation, while IL-13 carries out Th2 effector functions. As such, the present data suggest that the in vivo effect was primarily on Th2 differentiation, while the in vitro effect on differentiated human Th2 cells was

---

**Fig. 3.** DHA treatment inhibits the expression of IL-13 by human T helper type 2 (Th2) cells. Intracellular flow cytometry of phorbol myristate acetate (PMA) (P, 20 ng/ml)- and ionomycin (I, 1 μM)-stimulated Th2 cells in the presence or absence of DHA (10 μM). There was a significant inhibition of (a) IL-13 with DHA treatment (n = 12), which was not observed with (b) other lipids (n = 4). There was no difference in the percentage of IL-4-positive cells when stimulated in the presence of (c) DHA (n = 9) or (d) other lipids (n = 4). Statistical significance was assessed by (a, c) paired Student’s t test or (b, d) one-way ANOVA. Values are means, with standard errors represented by vertical bars. ** Mean value was significantly different from that of the other treatments (P < 0.01). AA, arachidonic acid; OA, oleic acid.
through the direct inhibition of IL-13 expression. We observed
the DHA-mediated inhibition of CREB binding to the IL-13
promoter; however, CREB \(-/-\) mice showed no major
alteration in IL-4 production\(^{(45)}\). Therefore, the difference in
IL-4 and IL-13 response to DHA may be attributed to their
relative dependence on CREB; however, further experiments
are needed to determine the underlying mechanism(s). 
Although Th2 cells stimulated in the presence of DHA exhib-
ited a reduction in the percentage of IL-13-expressing cells
in each experiment, there was an inverse relationship between
the inhibitory effect of DHA and the percentage of IL-13-
positive cells, indicating that higher concentrations of DHA
may have resulted in stronger inhibition in these cells.

Our in vitro data with human Th2 cells suggest that the
mechanism for the inhibitory effect of DHA on IL-13 involves
interference with CREB/ATF2 binding, subsequently reducing
transcriptional activation. Our previous studies showed that
DHA can be incorporated into lipid rafts within the plasma

![Figure 4](https://example.com/fig4.png)

**Fig. 4.** DHA treatment and IL-13 promoter regulation. Jurkat T cells transiently transfected with an IL-13 promoter reporter construct (IL-13-369pro/Luc) showed a
25-fold increase in promoter activity in response to an overnight treatment with phorbol myristate acetate (PMA) (P, 20 ng/ml) and ionomycin (I, 1 \(\mu\)M), and this
activity was inhibited (36\%) by (a) DHA (10 \(\mu\)M, \(n\) 7), but not by (b) other lipids (\(n\) 4). Statistical significance was assessed by (a) paired Student’s \(t\) test or (b)
one-way ANOVA. Values are means, with standard errors represented by vertical bars. Mean value was significantly different from that of the other treatments: \(* P < 0.05, ** P < 0.01.\)

![Figure 5](https://example.com/fig5.png)

**Fig. 5.** DHA treatment inhibits transcription factor binding to the IL-13 promoter. Electromobility shift assay with nuclear extracts from phorbol myristate acetate
(PMA) (20 ng/ml)- and ionomycin (1 \(\mu\)M)-stimulated (a) Jurkat and (b) CRTh2 \(^+\)Th2 cells show the binding of cyclic AMP response element binding (CREB) and
activating transcription factor 2 (ATF2) to the IL-13 promoter. Nuclear extracts from CRTh2 \(^+\)Th2 cells stimulated in the presence of (c) DHA (10 \(\mu\)M) show that the
binding of both CREB and ATF2 is reduced. Data are representative of four experiments. CRTh2, chemoattractant receptor-homologous molecule expressed on
T helper type 2 cells; Ab, antibody.
membrane and others have demonstrated its effects on signalling events regulating transcription factor activation/phosphorylation. For instance, DHA interferes with CD40-mediated NFκBp50 nuclear translocation and IL-4R-mediated signal transduction activator of transcription 6 (STAT6) phosphorylation, resulting in a reduction of class switching to IgE. DHA treatment has also been shown to inhibit CREB binding to the IL-6 promoter, through reduced phosphorylation of CREB and its kinase Akt. Akt is an important kinase in mediating T-cell activation through co-stimulatory signals such as CD28. This is likely to interrupt fundamental regulatory components of the IL-13 core promoter, since T-cell activation and the subsequent phosphorylation of CREB have been reported to mediate the binding of basic transcriptional machinery such as CBP and p300, which recruit RNA polymerase II. Another possibility is that CREB family members have been shown to interact with nuclear factor of activated T-cells (NFκB) when regulating genes such as cyclo-oxygenase 2 and TNF. NFAT is another factor that regulates IL-13 expression, and therefore the DHA effect on CREB phosphorylation and subsequent binding may also influence NFAT-mediated promoter activity. Our EMSA analysis investigated only one region of the IL-13 promoter and showed reduced binding of CREB/ATF2. However, it is also possible that some degree of the inhibitory effect of DHA on IL-13 expression resulted from influencing other regulatory elements. For instance, DHA inhibits the expression of NFκBp65, a transcription factor that induces IL-13 expression.

In addition to DHA acting as a direct inhibitor of IL-13 transcription, as we have shown, in vivo n-3 fatty acid supplementation may work through a number of mechanisms. For instance, the production of n-3 fatty acid metabolites such as Resolvin E1 has been shown to dampen allergic inflammation in a mouse model of asthma. Another mechanism may be through counterbalancing the level of n-6 fatty acid metabolites such as pro-inflammatory PGD2 and cysteinyl leukotrienes. For instance, a recent report has shown that human leukocytes obtained following 12 weeks of n-3 supplementation produced less cysteinyl leukotrienes.

There are also human studies which do not support a protective effect of n-3 fatty acids on the development of allergic disease, some of which have been discussed in a recent meta-analysis. However, studies showing positive and negative effects vary greatly in study design, n-3 formulation, dose, time and length of administration, outcome measure and heterogeneity of the population. Therefore, the effectiveness of n-3 supplementation may well depend on one or more of these factors. Careful reading of these studies indicates that conflicting results may be attributed to higher doses of DHA (2–4%), compared with the present study (1%). Furthermore, it is possible that an effect of n-3 fatty acid supplementation may not be observed in animal models if the sensitisation and/or challenge are too robust, overpowering the n-3 effect. In reality, sensitisation and the subsequent development of allergic disease are subtle events resulting from a tip in the balance between tolerance and sensitisation, and so experiments using animal models with mild sensitisation and challenge protocols may be needed to confirm the abrogation of sensitisation.

In conclusion, the present data suggest that dietary supplementation with n-3 fatty acids may help skew the balance away from allergic sensitisation by interfering with IL-13 promoter activation and IL-13 expression. These data are consistent with observational studies showing an association between n-3 fatty acid intake and reduced levels of cord blood IL-13 and the incidence of atopy and eczema, though further experiments are needed to determine whether n-3 fatty acids reduce allergic sensitisation and the development of allergic disease.

Acknowledgements

This study was supported by grants to: L. C. from the SickKids Foundation/Canadian Institutes of Health Research, the Alberta Heritage Foundation for Medical Research and the American Academy of Allergy, Asthma and Immunology; C. F. from the National Science and Engineering Council of Canada; H. V. from the Canadian Institutes Health Research. The authors also thank Susan Goruk, Chris Tse, Melanie Abel, Courtney Davidson and Jessica Storie for their technical assistance, as well as Donata Vercelli and Michael Kabesch for providing the IL-13-369pro/Luc reporter construct. E. M. performed the cell culture and EMSA analysis; N. M. performed the IL-13 reporter assays; H. V.’s laboratory performed the allergen sensitisation study; C. F.’s laboratory designed and generated the DHA and control diets, performed the splenocyte assays and the IL-13 ELISA; C. F. and H. V. also contributed to the manuscript writing; L. C. designed, coordinated and supervised the study and wrote the final manuscript.

There are no conflicts of interest to declare.

References

DHA inhibits IL-13 transcription

999


